Company registration number 10931005 (England and Wales)
INNOVAGEN LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
INNOVAGEN LIMITED
COMPANY INFORMATION
Directors
A Kaye
R Dummett
T Poole
M Johnson
Company number
10931005
Registered office
3rd Floor, St George's House
13-14 Ambrose Street
Cheltenham
GL50 3LG
Auditor
Arnold Hill & Co LLP
6th Floor Capital Tower
91 Waterloo Road
London
SE1 8RT
INNOVAGEN LIMITED
CONTENTS
Page
Directors' report
1
Directors' responsibilities statement
2
Independent auditor's report
3 - 5
Statement of comprehensive income
6
Statement of financial position
7
Statement of changes in equity
8
Notes to the financial statements
9 - 17
INNOVAGEN LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The directors present their annual report and financial statements for the year ended 31 December 2024.

Principal activities

The company's principal activity during the year continued to be developing a prototype end to end pyrolysis solution for converting waste into energy. The company is in a research and development phase with turnover generated from testing activities.

Results and dividends

The loss for the year amounted to £1,105,065 (2023: £965,143 loss). The directors do not recommend payment of any dividend for the year ended 31 December 2024 (2023: £nil).

Fair review of the business

The company has not yet started to trade and is currently in a development phase. The company has net liabilities at 31 December 2024 of £4,254,281 (2023: £3,149,216 net liabilities).

 

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

A Kaye
R Dummett
T Poole
M Johnson
Qualifying third party indemnity provisions

As permitted by the Companies Act 2006, the ultimate parent of the company, has indemnified the directors of the company in respect of proceedings brought by third parties and qualifying third party indemnity insurance was in place throughout the year and up to the date of approval of the financial statements.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

On behalf of the board
A Kaye
Director
8 September 2025
INNOVAGEN LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

 

 

INNOVAGEN LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBER OF INNOVAGEN LIMITED
- 3 -
Opinion

We have audited the financial statements of InnovaGen Limited (the 'company') for the year ended 31 December 2024 which comprise the statement of comprehensive income, the statement of financial position, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

INNOVAGEN LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBER OF INNOVAGEN LIMITED (CONTINUED)
- 4 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit, in respect to fraud, are: to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses; and to respond appropriately to fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and its management.

Our approach was as follows:

INNOVAGEN LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBER OF INNOVAGEN LIMITED (CONTINUED)
- 5 -

Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Where the risk was considered to be higher, we performed audit procedures to address each identified fraud risk. These procedures included: testing manual journals; reviewing the financial statement disclosures and testing to supporting documentation; performing analytical procedures; and enquiring of management, and were designed to provide reasonable assurance that the financial statements were free from fraud or error.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's member in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's member those matters we are required to state to the member in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's member, for our audit work, for this report, or for the opinions we have formed.

Dipesh Giri BSc (Hons) BFP ACA
Senior Statutory Auditor
For and on behalf of Arnold Hill & Co LLP
8 September 2025
Chartered Accountants
Statutory Auditor
6th Floor Capital Tower
91 Waterloo Road
London
SE1 8RT
INNOVAGEN LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
2024
2023
Notes
£
£
Turnover
13,204
35,561
Cost of sales
(706,062)
(623,293)
Gross loss
(692,858)
(587,732)
Administrative expenses
(246,874)
(283,218)
Other operating income
-
0
110
Operating loss
3
(939,732)
(870,840)
Interest receivable and similar income
6
-
0
70
Interest payable and similar expenses
7
(262,444)
(190,989)
Loss before taxation
(1,202,176)
(1,061,759)
Tax on loss
8
97,111
96,616
Loss for the financial year
(1,105,065)
(965,143)

The income statement has been prepared on the basis that all operations are continuing operations.

The notes on pages 9 to 17 form part of these financial statements.

INNOVAGEN LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2024
31 December 2024
- 7 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
9
66,553
114,172
Current assets
Debtors
10
166,891
164,067
Cash at bank and in hand
33,276
10,870
200,167
174,937
Creditors: amounts falling due within one year
11
(4,521,001)
(3,438,325)
Net current liabilities
(4,320,834)
(3,263,388)
Net liabilities
(4,254,281)
(3,149,216)
Capital and reserves
Called up share capital
13
100
100
Profit and loss reserves
(4,254,381)
(3,149,316)
Total equity
(4,254,281)
(3,149,216)

The notes on pages 9 to 17 form part of these financial statements.

The financial statements were approved by the board of directors and authorised for issue on 8 September 2025 and are signed on its behalf by:
A Kaye
Director
Company registration number 10931005 (England and Wales)
INNOVAGEN LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2023
100
(2,184,173)
(2,184,073)
Period ended 31 December 2023:
Loss and total comprehensive income
-
(965,143)
(965,143)
Balance at 31 December 2023
100
(3,149,316)
(3,149,216)
Year ended 31 December 2024:
Loss and total comprehensive income
-
(1,105,065)
(1,105,065)
Balance at 31 December 2024
100
(4,254,381)
(4,254,281)

The notes on pages 9 to 17 form part of these financial statements.

INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
1
Accounting policies
Company information

InnovaGen Limited is a private company limited by shares incorporated in England and Wales. The registered office is 3rd Floor, St George's House, 13-14 Ambrose Street, Cheltenham, GL50 3LG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements of Innova Renewables Limited. These consolidated financial statements are available from its registered office, 3rd Floor, St George's House, 13-14 Ambrose Street, Cheltenham, GL50 3LG.

1.2
Going concern

The directors have have considered a period of 12 months from the date of approval of thesetrue financial statements in preparing their going concern assessment. The going concern assessment is dependent on the ultimate parent, Innova Capital Limited, not seeking repayment of the amounts due to other group entities that are controlled by Innova Capital Limited for a period of at least 12 months from the date of signing these financial statements. Innova Capital Limited has indicated its intention to continue to make available such funds as are needed by the company and that it does not intend to seek repayment of the amounts due during the going concern assessment period.

 

Consequently, the directors have are confident that the company will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.

1.3
Turnover

Turnover is measured at the fair value of consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the process of converting waste to energy.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 10 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Over 10 years straight line basis
Plant and equipment
Over 3 years straight line basis
Fixtures and fittings
Over 3 years straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 11 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

 

Group relief is charged on the surrender of tax losses between group companies at a rate of 75% of the tax value.

INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 12 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The directors do not consider there to be any material critical judgements.

 

Key sources of estimation uncertainty

The directors do not consider there to be any material key sources of estimation uncertainty.

 

 

 

 

3
Operating loss
2024
2023
Operating loss for the year is stated after charging/(crediting):
£
£
Exchange (gains)/losses
(1,306)
84
Research and development costs
546,699
486,006
Fees payable to the company's auditor for the audit of the company's financial statements
6,000
6,000
Depreciation of owned tangible fixed assets
53,363
47,545
Operating lease charges
34,797
23,502
INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 13 -
4
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Operations
7
6

Their aggregate remuneration comprised:

2024
2023
£
£
Wages and salaries
378,617
320,316
Social security costs
42,512
36,750
Pension costs
14,342
16,966
435,471
374,032
5
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
107,658
41,216
6
Interest receivable and similar income
2024
2023
£
£
Interest income
Other interest income
-
0
70
7
Interest payable and similar expenses
2024
2023
£
£
Other interest on financial liabilities
262,444
190,989
8
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
(97,111)
(96,616)
INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
8
Taxation
(Continued)
- 14 -

From 5 April 2023, the main rate of corporation tax increased from 19% to 25%, and a new 19% small profits rate of corporation tax was introduced for companies whose profits do not exceed £50,000. The main rate applies to companies with profits in excess of £250,000.

 

Due to the size of the company the rate used for this 12 month period is 19% (2023: 24%).

The actual credit for the year can be reconciled to the expected credit for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Loss before taxation
(1,202,176)
(1,061,759)
Expected tax credit based on the standard rate of corporation tax in the UK of 19.00% (2023: 23.50%)
(228,413)
(249,513)
Unutilised tax losses carried forward
228,413
249,513
Research and development tax credit
(97,111)
(96,616)
Taxation credit for the year
(97,111)
(96,616)

Total carried forward losses for tax purposes at the end of the year was £2,308,274 (2023: £1,106,098).

9
Tangible fixed assets
Leasehold land and buildings
Plant and equipment
Fixtures and fittings
Total
£
£
£
£
Cost
At 1 January 2024
22,609
161,374
2,367
186,350
Additions
-
0
-
0
5,744
5,744
At 31 December 2024
22,609
161,374
8,111
192,094
Depreciation and impairment
At 1 January 2024
2,208
69,407
563
72,178
Depreciation charged in the year
2,261
49,136
1,966
53,363
At 31 December 2024
4,469
118,543
2,529
125,541
Carrying amount
At 31 December 2024
18,140
42,831
5,582
66,553
At 31 December 2023
20,401
91,967
1,804
114,172
INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 15 -
10
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
1,166
1,908
Corporation tax recoverable
97,111
96,604
Other debtors
25,043
27,977
Prepayments and accrued income
43,571
37,578
166,891
164,067
11
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
14,647
38,971
Amounts owed to related parties
3,826,322
2,802,068
Other creditors
199,359
181,716
Accruals and deferred income
480,673
415,570
4,521,001
3,438,325
12
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
14,342
16,966

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

13
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of 1p each
8,645
8,645
86
86
Ordinary B shares of 1p each
1,355
1,355
14
14
10,000
10,000
100
100

The company has class A & B Ordinary shares, with each class holding full rights regarding voting, payment of dividends and distributions.

14
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
14
Related party transactions
(Continued)
- 16 -
Sales
Sales
Purchases
Purchases
2024
2023
2024
2023
£
£
£
£
Entities with control, joint control or significant influence over the company
417
-
0
16,847
20,438
Other related parties
420
23,399
46,109
105,173
Loans from
2024
2023
£
£
Entities with control, joint control or significant influence over the company
1,069,140
1,012,481
2024
2023
Amounts due to related parties
£
£
Entities with control, joint control or significant influence over the company
3,826,320
2,982,934
Key management personnel
182,822
169,245
Other related parties
-
52,113

During the year sales of £417 (2023: £23,399) were made to Innova Renewables Limited, a company within the Innova Capital Limited group, which also has A Kaye and R Dummett as directors. The company made purchases of £23,370 (2023: £49,989) from Innova Renewables Limited and amounts due at year end was £nil (2023: £52,113).

 

During the year the company made purchases of £22,739 (2023: £55,183) from Beech Farm Trading Limited, a company owned by T Poole, director of the company. The company also made sales of £420 (2023: £nil) during the year to Beech Farm Trading Limited. Amounts due at the year end were £nil (2023: £nil).

 

During the year loans were made to the company of £1,069,140 (2023: £1,012,481) from Innova Capital Limited, the company's ultimate parent entity, on which interest of £248,867 (2023: £174,561) was charged. Interest is accrued at a rate of 8% of the outstanding balance and the loan is repayable on demand. The amounts due at the year end was £3,826,320 (2023: £2,757,180). Other amounts owed to Innova Capital Limited include £nil (2023: £225,754) for accrued staff costs and other amounts.

 

Amounts owed to key management personnel includes a loan from Beech Farm Trading Limited, a company owned by Trevor Poole, director of the company. During the year the loan accrued interest of £13,577 (2022: £12,537) which was included in the amounts due at the year end of £349,489 (2023: £335,912). Interest is accrued at a rate of 8% of the outstanding balance and the loan is repayable on demand.

Transactions with related parties were done at market rate and are repayable on demand.

INNOVAGEN LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 17 -
15
Ultimate controlling party

As at 31 December 2024 the company's immediate parent and ultimate parent company is Innova Capital Limited, where the company's results are consolidated. Both entities were incorporated in England and Wales and have the same registered address of 3rd Floor, St George's House, 13-14 Ambrose Street, Cheltenham, GL50 3LG.

There is no ultimate controlling party as no one individual is considered to have a majority shareholding.

2024-12-312024-01-01falseCCH SoftwareCCH Accounts Production 2024.100A KayeR DummettT PooleM Johnsonfalsefalse109310052024-01-012024-12-3110931005bus:Director12024-01-012024-12-3110931005bus:Director22024-01-012024-12-3110931005bus:Director32024-01-012024-12-3110931005bus:Director42024-01-012024-12-3110931005bus:RegisteredOffice2024-01-012024-12-31109310052024-12-31109310052023-01-012023-12-3110931005core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3110931005core:RetainedEarningsAccumulatedLosses2024-01-012024-12-31109310052023-12-3110931005core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3110931005core:PlantMachinery2024-12-3110931005core:FurnitureFittings2024-12-3110931005core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3110931005core:PlantMachinery2023-12-3110931005core:FurnitureFittings2023-12-3110931005core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3110931005core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3110931005core:CurrentFinancialInstruments2024-12-3110931005core:CurrentFinancialInstruments2023-12-3110931005core:ShareCapital2024-12-3110931005core:ShareCapital2023-12-3110931005core:RetainedEarningsAccumulatedLosses2024-12-3110931005core:RetainedEarningsAccumulatedLosses2023-12-3110931005core:ShareCapital2022-12-3110931005core:RetainedEarningsAccumulatedLosses2022-12-3110931005core:ShareCapitalOrdinaryShares2024-12-3110931005core:ShareCapitalOrdinaryShares2023-12-3110931005core:LandBuildingscore:LongLeaseholdAssets2024-01-012024-12-3110931005core:PlantMachinery2024-01-012024-12-3110931005core:FurnitureFittings2024-01-012024-12-3110931005core:UKTax2024-01-012024-12-3110931005core:UKTax2023-01-012023-12-3110931005core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3110931005core:PlantMachinery2023-12-3110931005core:FurnitureFittings2023-12-31109310052023-12-3110931005core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-01-012024-12-3110931005core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntitycore:SaleOrPurchaseGoods2024-01-012024-12-3110931005core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntitycore:SaleOrPurchaseGoods2023-01-012023-12-3110931005core:OtherRelatedPartiescore:SaleOrPurchaseGoods2024-01-012024-12-3110931005core:OtherRelatedPartiescore:SaleOrPurchaseGoods2023-01-012023-12-3110931005core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity2024-12-3110931005bus:PrivateLimitedCompanyLtd2024-01-012024-12-3110931005bus:FRS1022024-01-012024-12-3110931005bus:Audited2024-01-012024-12-3110931005bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP